Patients’ Pathologic Stage, Tumor Response, 18F-FDG PET Parameters, Radiation Dose, and Survival Data
| Patient no. | Pathologic stage (at surgery) | TRG | Pretreatment SUVmax | Intratreatment SUVmax* | %ΔSUVmax | | Δ | uptake time (min) | Interval from start of chemoradiotherapy to intratreatment PET (d) | Radiotherapy dose at time of intratreatment PET (Gy) | Interval from end of chemoradiotherapy to surgery (d) | Survival from start of chemoradiotherapy (d) | Alive at time of analysis |
| 1 | T0N1MX | Responder | 6.3 | 5.9 | −6.3 | 1 | 10 | 21.4 | 70 | 302 | No |
| 2 | T0N0MX | Responder | 9.8 | 9.5 | −3.1 | 7 | 13 | 24.0 | 37 | 832 | Yes |
| 3 | T0N0MX | Responder | 12.3 | 12.9 | 4.9 | 8 | 14 | 20.0 | 58 | 1034 | Yes |
| 4 | T3N1MX | Responder | 8.3 | 4.1 | −50.8 | 2 | 14 | 26.7 | 61 | 209 | Yes |
| 5 | T1N1MX | Responder | 12.1 | 5.1 | −57.9 | 14 | 14 | 26.7 | 53 | 237 | Yes |
| 6 | T3N1MX | Responder | 5.4 | 3.6 | −33.3 | 5 | 14 | 26.7 | 41 | 237 | Yes |
| 7 | T1N1MX | Responder | 3.9 | 3.5 | −10.3 | 6 | 9 | 18.7 | 56 | 371 | Yes |
| 8 | T1N0MX | Responder | 5.3 | 3.9 | −26.4 | 3 | 10 | 21.4 | 50 | 519 | Yes |
| 9 | T0N1MX | Responder | 7.4 | 4.7 | −36.5 | 5 | 14 | 26.7 | 39 | 540 | No |
| 10 | T3N1MX | Responder | 12.4 | 4.8 | −61.3 | 2 | 12 | 26.7 | 43 | 574 | No |
| 11 | T0N0MX | Responder | 10.6 | 4.2 | −60.4 | 4 | 14 | 26.7 | 40 | 579 | Yes |
| 12 | T1N0MX | Responder | 19.6 | 6.8 | −65.3 | 10 | 12 | 20.0 | 25 | 653 | No |
| 13 | T3N0MX | Responder | 19.1 | 13.0 | −31.9 | 4 | 14 | 26.7 | 58 | 1428 | Yes |
| 14 | T1N0MX | Responder | 19.2 | 8.9 | −53.6 | 1 | 12 | 26.7 | 46 | 1457 | Yes |
| 15 | T1N0MX | Responder | 3.9 | 3.5 | −10.3 | 0 | 14 | 26.7 | 60 | 1483 | Yes |
| 16 | T1N0MX | Responder | 4.3 | 4.3 | 0.0 | 5 | 14 | 20.0 | 46 | 1519 | Yes |
| 17 | T3N1MX | Nonresponder | 5.0 | 5.6 | 12.0 | 3 | 14 | 26.7 | 46 | 237 | Yes |
| 18 | T3N1MX | Nonresponder | 6.4 | 5.3 | −17.2 | 17 | 10 | 21.4 | 75 | 277 | No |
| 19 | T3N1MX | Nonresponder | 9.3 | 4.7 | −49.5 | 0 | 13 | 24.0 | 88 | 292 | No |
| 20 | T3N1MX | Nonresponder | 8.4 | 8.6 | 2.4 | 1 | 11 | 24.0 | 51 | 288 | No |
| 21 | T3N1MX | Nonresponder | 10.4 | 5.3 | −49.0 | 4 | 14 | 26.7 | 91 | 348 | Yes |
| 22 | T3N1MX | Nonresponder | 6.2 | 5.1 | −17.7 | 2 | 10 | 21.4 | 56 | 331 | No |
| 23 | T3N1MX | Nonresponder | 12.1 | 5.4 | −55.4 | 11 | 14 | 26.7 | 43 | 383 | No |
| 24 | T2N1MX | Nonresponder | 20.9 | 18.3 | −12.4 | 7 | 14 | 26.7 | 60 | 581 | No |
| 25 | T2N1MX | Nonresponder | 5.6 | 5.7 | 1.8 | 10 | 11 | 24.0 | 67 | 595 | No |
| 26 | T3N1MX | Nonresponder | 5.7 | 4.1 | −28.1 | 10 | 11 | 24.0 | 30 | 627 | No |
| 27 | T3N1MX | Nonresponder | 8.2 | 8.5 | 3.7 | 15 | 12 | 26.7 | 52 | 723 | No |
| 28 | T3N0MX | Nonresponder | 10.6 | 8.1 | −23.6 | 8 | 12 | 26.7 | 42 | 723 | Yes |
| 29 | T3N0MX | Nonresponder | 6.0 | 7.3 | 21.7 | 6 | 14 | 20.0 | 63 | 778 | No |
| 30 | T2N0MX | Nonresponder | 12.6 | 11.8 | −6.3 | 0 | 10 | 21.4 | 52 | 799 | Yes |
| 31 | T3N1MX | Nonresponder | 10.0 | 5.1 | −48.7 | 8 | 12 | 26.7 | 47 | 799 | Yes |
| 32 | T3N1MX | Nonresponder | 6.4 | 5.9 | −7.8 | 4 | 9 | 18.7 | 37 | 1282 | Yes |
| 33 | T3N1MX | Nonresponder | 5.2 | 4.8 | −7.7 | 3 | 12 | 26.7 | 54 | 456 | No |
| 34 | T3N1MX | Nonresponder | 6.2 | 3.5 | −43.5 | 12 | 12 | 26.7 | 44 | 449 | No |
| 35 | T3N1MX | Nonresponder | 6.4 | 6.9 | 7.8 | 3 | 14 | 26.7 | 56 | 518 | Yes |
| 36 | T3N1MX | Nonresponder | 5.7 | 4.5 | −21.1 | 5 | 12 | 20.0 | 28 | 631 | No |
| 37 | T3N0MX | Nonresponder | 9.5 | 7.0 | −26.3 | 0 | 11 | 24.0 | 56 | 669 | No |
| Mean | 6 | 12 | 24.2 | 52 | |||||||
| Range | 1–17 | 9–14 | 18.7–26.7 | 25–91 | |||||||
| SD | 4 | 2 | 2.9 | 14 |
↵* 2 wk after start of chemoradiotherapy.